Gregory Verghese

Gregory Verghese

Auto-generated profile, based on publicly available information

Gregory Verghese

Cancer Bioinformatics, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine King's College London London UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in The Journal of Pathology
Verified
Journal Article
Open access
GVGregory Verghese
Gregory Verghese
JLJochen K Lennerz
Jochen K Lennerz
DRDanny Ruta
Danny Ruta
WNWen Ng
Wen Ng
STSelvam Thavaraj
Selvam Thavaraj
AGAnita Grigoriadis
Anita Grigoriadis
Computational pathology refers to applying deep learning techniques and algorithms to analyse and interpret histopathology images. Advances in artificial intelligence (AI) have led to an explosion in innovation in computational pathology, ranging from the prospect of automation of routine diagnostic tasks to the discovery of new prognostic and predictive biomarkers from tissue morphology. Despite the promising potential of computational pathology, its integration in clinical settings has been limited by a range of obstacles including operational, technical, regulatory, ethical, financial, and cultural challenges. Here, we focus on the pathologists’ perspective of computational pathology: we map its current translational research landscape, evaluate its clinical utility, and address the more common challenges slowing clinical adoption and implementation. We conclude by describing contemporary approaches to drive forward these techniques. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

23 August 2023 in The Journal of Pathology
Verified
Journal Article
Open access
JTJeppe Thagaard
Jeppe Thagaard
GBGlenn Broeckx
Glenn Broeckx
DPDavid B Page
David B Page
CJChowdhury Arif Jahangir
Chowdhury Arif Jahangir
SVSara Verbandt
Sara Verbandt
ESElisabeth Specht Stovgaard
Elisabeth Specht Stovgaard
The clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen receptor, progesterone receptor, and HER2‐negative) breast cancer and HER2‐positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state‐of‐the‐art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false‐positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in‐depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple‐negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

23 August 2023 in The Journal of Pathology
Verified
Journal Article
Closed access
DPDavid B Page
David B Page
GBGlenn Broeckx
Glenn Broeckx
CJChowdhury Arif Jahangir
Chowdhury Arif Jahangir
SVSara Verbandt
Sara Verbandt
RGRajarsi Gupta
Rajarsi Gupta
ESElisabeth Specht Stovgaard
Elisabeth Specht Stovgaard

17 January 2024 in The Journal of Pathology
Verified
Journal Article
Open access
CJChowdhury Arif Jahangir
Chowdhury Arif Jahangir
DPDavid B Page
David B Page
GBGlenn Broeckx
Glenn Broeckx
CGClaudia A Gonzalez
Claudia A Gonzalez
CBCaoimbhe Burke
Caoimbhe Burke
ARArman Rahman
Arman Rahman
Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

13 August 2022 in arXiv
Verified
Preprint
Open access
PDF file
NKNikhil Cherian Kurian
Nikhil Cherian Kurian
ALAmit Lohan
Amit Lohan
GVGregory Verghese
Gregory Verghese
NDNimish Dharamshi
Nimish Dharamshi
SMSwati Meena
Swati Meena
ASAmit Sethi
Amit Sethi
Although the U-Net architecture has been extensively used for segmentation of medical images, we address two of its shortcomings in this work. Firstly, the accuracy of vanilla U-Net degrades when the target regions for segmentation exhibit significant variations in shape and size. Even though the U-Net already possesses some capability to analyze features at various scales, we propose to explicitly add multi-scale feature maps in each convolutional module of the U-Net encoder to improve segmentation of histology images. Secondly, the accuracy of a U-Net model also suffers when the annotations for supervised learning are noisy or incomplete. This can happen due to the inherent difficulty for a human expert to identify and delineate all instances of specific pathology very precisely and accurately. We address this challenge by introducing auxiliary confidence maps that emphasize less on the boundaries of the given target regions. Further, we utilize the bootstrapping properties of the deep network to address the missing annotation problem intelligently. In our experiments on a private dataset of breast cancer lymph nodes, where the primary task was to segment germinal centres and sinus histiocytosis, we observed substantial improvement over a U-Net baseline based on the two proposed augmentations.